The Membrane Interactions of Synuclein: Physiology and Pathology

Literature Cited

1. 1. 

   Selkoe DJ, Hardy J. 2016. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med 8:595–608
   [Google Scholar]
2. 2. 

   Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A et al. 2000. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J. Neurosci 20:7951–63
   [Google Scholar]
3. 3. 

   Wang P, Yang G, Mosier DR, Chang P, Zaidi T et al. 2005. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. J. Neurosci 25:1219–25
   [Google Scholar]
4. 4. 

   Ballatore C, Lee VM, Trojanowski JQ. 2007. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci 8:663–72
   [Google Scholar]
5. 5. 

   Wang Y, Mandelkow E. 2016. Tau in physiology and pathology. Nat. Rev. Neurosci 17:5–21
   [Google Scholar]
6. 6. 

   Goedert M, Spillantini MG, Del Tredici K, Braak H. 2013. 100 years of Lewy pathology. Nat. Rev. Neurol. 9:13–24
   [Google Scholar]
7. 7. 

   Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M 1997. α-Synuclein in Lewy bodies. Nature 388:839–40
   [Google Scholar]
8. 8. 

   Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A et al. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276:2045–47
   [Google Scholar]
9. 9. 

   Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M et al. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Gen 18:106–8
   [Google Scholar]
10. 10. 

    Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R et al. 2004. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55:164–73
    [Google Scholar]
11. 11. 

    Singleton AB, Farrer M, Johnson J, Singleton A, Hague S et al. 2003. α-Synuclein locus triplication causes Parkinson's disease. Science 302:841
    [Google Scholar]
12. 12. 

    Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR et al. 2009. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Gen. 41:1308–12
    [Google Scholar]
13. 13. 

    Soldner F, Stelzer Y, Shivalila CS, Abraham BJ, Latourelle JC et al. 2016. Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. Nature 533:95–99
    [Google Scholar]
14. 14. 

    Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24:197–211
    [Google Scholar]
15. 15. 

    Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P et al. 2012. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949–53
    [Google Scholar]
16. 16. 

    Watts JC, Giles K, Oehler A, Middleton L, Dexter DT et al. 2013. Transmission of multiple system atrophy prions to transgenic mice. PNAS 110:19555–60
    [Google Scholar]
17. 17. 

    Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A et al. 2018. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies. Nature 557:558–63
    [Google Scholar]
18. 18. 

    Woerman AL, Stohr J, Aoyagi A, Rampersaud R, Krejciova Z et al. 2015. Propagation of prions causing synucleinopathies in cultured cells. PNAS 112:E4949–58
    [Google Scholar]
19. 19. 

    Conway KA, Harper JD, Lansbury PT. 1998. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med 4:1318–20
    [Google Scholar]
20. 20. 

    Volles MJ, Lansbury PT Jr. 2007. Relationships between the sequence of α-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J. Mol. Biol. 366:1510–22
    [Google Scholar]
21. 21. 

    Maroteaux L, Campanelli JT, Scheller RH. 1988. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8:2804–15
    [Google Scholar]
22. 22. 

    Nakajo S, Omata K, Aiuchi T, Shibayama T, Okahashi I et al. 1990. Purification and characterization of a novel brain-specific 14-kDa protein. J. Neurochem 55:2031–38
    [Google Scholar]
23. 23. 

    Jakes R, Spillantini MG, Goedert M. 1994. Identification of two distinct synucleins from human brain. FEBS Lett 345:27–32
    [Google Scholar]
24. 24. 

    Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A et al. 1993. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. PNAS 90:11282–86
    [Google Scholar]
25. 25. 

    Masters CL, Selkoe DJ. 2012. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med 2:a006262
    [Google Scholar]
26. 26. 

    Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L et al. 1995. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467–75
    [Google Scholar]
27. 27. 

    George JM, Jin H, Woods WS, Clayton DF. 1995. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361–72
    [Google Scholar]
28. 28. 

    Kholodilov NG, Neystat M, Oo TF, Lo SE, Larsen KE et al. 1999. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J. Neurochem 73:2586–99
    [Google Scholar]
29. 29. 

    Busch DJ, Morgan JR. 2012. Synuclein accumulation is associated with cell-specific neuronal death after spinal cord injury. J. Comp. Neurol 520:1751–71
    [Google Scholar]
30. 30. 

    Beatman EL, Massey A, Shives KD, Burrack KS, Chamanian M et al. 2015. Alpha-synuclein expression restricts RNA viral infections in the brain. J. Virol 90:2767–82
    [Google Scholar]
31. 31. 

    Davidson WS, Jonas A, Clayton DF, George JM 1998. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem 273:9443–49
    [Google Scholar]
32. 32. 

    Bussell R Jr., Eliezer D. 2003. A structural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol. 329:763–78
    [Google Scholar]
33. 33. 

    Jao CC, Der-Sarkissian A, Chen J, Langen R 2004. Structure of membrane-bound α-synuclein studied by site-directed spin labeling. PNAS 101:8331–36
    [Google Scholar]
34. 34. 

    Bodner CR, Dobson CM, Bax A. 2009. Multiple tight phospholipid-binding modes of α-synuclein revealed by solution NMR spectroscopy. J. Mol. Biol. 390:775–90
    [Google Scholar]
35. 35. 

    Čopič A, Antoine-Bally S, Giménez-Andrés M, La Torre Garay C, Antonny B et al. 2018. A giant amphipathic helix from a perilipin that is adapted for coating lipid droplets. Nat. Commun. 9:1332
    [Google Scholar]
36. 36. 

    Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH. 2004. Lipid rafts mediate the synaptic localization of α-synuclein. J. Neurosci 24:6715–23
    [Google Scholar]
37. 37. 

    Withers GS, George JM, Banker GA, Clayton DF. 1997. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Dev. Brain Res 99:87–94
    [Google Scholar]
38. 38. 

    Nakamura K, Nemani VM, Kaehlcke K, Ott M, Edwards RH. 2008. Optical reporters for the conformation of α-synuclein reveal a specific interaction with mitochondria. J. Neurosci 28:12305–17
    [Google Scholar]
39. 39. 

    Lautenschlager J, Stephens AD, Fusco G, Strohl F, Curry N et al. 2018. C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction. Nat. Commun 9:712
    [Google Scholar]
40. 40. 

    Boassa D, Berlanga ML, Yang MA, Terada M, Hu J et al. 2013. Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis. J. Neurosci 33:2605–15
    [Google Scholar]
41. 41. 

    Vargas KJ, Schrod N, Davis T, Fernandez-Busnadiego R, Taguchi YV et al. 2017. Synucleins have multiple effects on presynaptic architecture. Cell Rep 18:161–73
    [Google Scholar]
42. 42. 

    Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M. 1998. Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem 273:26292–94
    [Google Scholar]
43. 43. 

    Unni VK, Weissman TA, Rockenstein E, Masliah E, McLean PJ, Hyman BT. 2010. In vivo imaging of α-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLOS ONE 5:e10589
    [Google Scholar]
44. 44. 

    Zabrocki P, Bastiaens I, Delay C, Bammens T, Ghillebert R et al. 2008. Phosphorylation, lipid raft interaction and traffic of α-synuclein in a yeast model for Parkinson. Biochim. Biophys. Acta Mol. Cell Res 1783:1767–80
    [Google Scholar]
45. 45. 

    Kubo SI, Nemani VM, Chalkley RJ, Anthony MD, Hattori N et al. 2005. A combinatorial code for the interaction of α-synuclein with membranes. J. Biol. Chem 280:31664–72
    [Google Scholar]
46. 46. 

    Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL. 2002. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein α-synuclein. J. Biol. Chem 277:6344–52
    [Google Scholar]
47. 47. 

    Millership S, Ninkina N, Guschina IA, Norton J, Brambilla R et al. 2012. Increased lipolysis and altered lipid homeostasis protect γ-synuclein–null mutant mice from diet-induced obesity. PNAS 109:20943–48
    [Google Scholar]
48. 48. 

    Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ 2001. α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. PNAS 98:9110–15
    [Google Scholar]
49. 49. 

    Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. 2003. The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37:583–95
    [Google Scholar]
50. 50. 

    Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, Selkoe DJ. 2003. Altered fatty acid composition of dopaminergic neurons expressing α-synuclein and human brains with α-synucleinopathies. J. Biol. Chem 278:49874–81
    [Google Scholar]
51. 51. 

    Ellis CE, Murphy EJ, Mitchell DC, Golovko MY, Scaglia F et al. 2005. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking α-synuclein. Mol. Cell. Biol 25:10190–201
    [Google Scholar]
52. 52. 

    Fanning S, Haque A, Imberdis T, Baru V, Barrasa MI et al. 2019. Lipidomic analysis of α-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment. Mol. Cell 73:1001–14.e8
    [Google Scholar]
53. 53. 

    Stefani G, Onofri F, Valtorta F, Vaccaro P, Greengard P, Benfenati F. 1997. Kinetic analysis of the phosphorylation-dependent interactions of synapsin I with rat brain synaptic vesicles. J. Physiol 504:Pt 3501–15
    [Google Scholar]
54. 54. 

    Hosaka M, Hammer RE, Sudhof TC. 1999. A phospho-switch controls the dynamic association of synapsins with synaptic vesicles. Neuron 24:377–87
    [Google Scholar]
55. 55. 

    Chi P, Greengard P, Ryan TA. 2001. Synapsin dispersion and reclustering during synaptic activity. Nat. Neurosci 4:1187–93
    [Google Scholar]
56. 56. 

    Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH. 2005. Neural activity controls the synaptic accumulation of α-synuclein. J. Neurosci 25:10913–21
    [Google Scholar]
57. 57. 

    Tao-Cheng JH. 2006. Activity-related redistribution of presynaptic proteins at the active zone. Neuroscience 141:1217–24
    [Google Scholar]
58. 58. 

    Comellas G, Lemkau LR, Zhou DH, George JM, Rienstra CM. 2012. Structural intermediates during α-synuclein fibrillogenesis on phospholipid vesicles. J. Am. Chem. Soc 134:5090–99
    [Google Scholar]
59. 59. 

    Dikiy I, Eliezer D. 2012. Folding and misfolding of alpha-synuclein on membranes. Biochim. Biophys. Acta Biomembr 1818:1013–18
    [Google Scholar]
60. 60. 

    Lee HJ, Choi C, Lee SJ. 2002. Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem 277:671–78
    [Google Scholar]
61. 61. 

    Zhu M, Fink AL. 2003. Lipid binding inhibits α-synuclein fibril formation. J. Biol. Chem 278:16873–77
    [Google Scholar]
62. 62. 

    Soper JH, Kehm V, Burd CG, Bankaitis VA, Lee VM. 2010. Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis. J. Mol. Neurosci 43:391–405
    [Google Scholar]
63. 63. 

    Diao J, Burre J, Vivona S, Cipriano DJ, Sharma M et al. 2013. Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. eLife 2:e00592
    [Google Scholar]
64. 64. 

    Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L et al. 2011. In vivo demonstration that α-synuclein oligomers are toxic. PNAS 108:4194–99
    [Google Scholar]
65. 65. 

    Bartels T, Choi JG, Selkoe DJ. 2011. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477:107–10
    [Google Scholar]
66. 66. 

    Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D. 2013. In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J. Biol. Chem 288:6371–85
    [Google Scholar]
67. 67. 

    Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S et al. 2012. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem 287:15345–64
    [Google Scholar]
68. 68. 

    Theillet FX, Binolfi A, Bekei B, Martorana A, Rose HM et al. 2016. Structural disorder of monomeric α-synuclein persists in mammalian cells. Nature 530:45–50
    [Google Scholar]
69. 69. 

    Burre J, Sharma M, Sudhof TC 2014. α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. PNAS 111:E4274–83
    [Google Scholar]
70. 70. 

    Wang L, Das U, Scott DA, Tang Y, McLean PJ, Roy S 2014. α-Synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol 24:2319–26
    [Google Scholar]
71. 71. 

    Choi BK, Choi MG, Kim JY, Yang Y, Lai Y et al. 2013. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. PNAS 110:4087–92
    [Google Scholar]
72. 72. 

    DeWitt DC, Rhoades E. 2013. α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers. Biochemistry 52:2385–87
    [Google Scholar]
73. 73. 

    Lai Y, Kim S, Varkey J, Lou X, Song JK et al. 2014. Nonaggregated α-synuclein influences SNARE-dependent vesicle docking via membrane binding. Biochemistry 53:3889–96
    [Google Scholar]
74. 74. 

    Dettmer U, Newman AJ, Soldner F, Luth ES, Kim NC et al. 2015. Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun 6:7314
    [Google Scholar]
75. 75. 

    Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34:521–33
    [Google Scholar]
76. 76. 

    Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ et al. 2003. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci 24:419–29
    [Google Scholar]
77. 77. 

    Tofaris GK, Garcia Reitböck P, Humby T, Lambourne SL, O'Connell M et al. 2006. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1–120): implications for Lewy body disorders. J. Neurosci 26:3942–50
    [Google Scholar]
78. 78. 

    Lundblad M, Decressac M, Mattsson B, Bjorklund A 2012. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. PNAS 109:3213–19
    [Google Scholar]
79. 79. 

    Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M et al. 2000. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287:1265–69
    [Google Scholar]
80. 80. 

    Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW et al. 2002. Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res 68:568–78
    [Google Scholar]
81. 81. 

    Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF. 2008. Olfactory deficits in mice overexpressing human wildtype α-synuclein. Eur. J. Neurosci 28:247–56
    [Google Scholar]
82. 82. 

    Shults CW, Rockenstein E, Crews L, Adame A, Mante M et al. 2005. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J. Neurosci 25:10689–99
    [Google Scholar]
83. 83. 

    Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S et al. 2005. Mouse model of multiple system atrophy α-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847–59
    [Google Scholar]
84. 84. 

    Nuber S, Rajsombath M, Minakaki G, Winkler J, Muller CP et al. 2018. Abrogating native α-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome closely resembling Parkinson's disease. Neuron 100:75–90.e5
    [Google Scholar]
85. 85. 

    Yavich L, Oksman M, Tanila H, Kerokoski P, Hiltunen M et al. 2005. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human α-synuclein. Neurobiol. Dis 20:303–13
    [Google Scholar]
86. 86. 

    Janezic S, Threlfell S, Dodson PD, Dowie MJ, Taylor TN et al. 2013. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. PNAS 110:E4016–25
    [Google Scholar]
87. 87. 

    Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P et al. 2006. α-Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci 26:11915–22
    [Google Scholar]
88. 88. 

    Nemani VM, Lu W, Berge V, Nakamura K, Onoa B et al. 2010. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65:66–79
    [Google Scholar]
89. 89. 

    Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S 2010. A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration. J. Neurosci 30:8083–95
    [Google Scholar]
90. 90. 

    Larson ME, Greimel SJ, Amar F, LaCroix M, Boyle G et al. 2017. Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits. PNAS 114:E4648–57
    [Google Scholar]
91. 91. 

    Atias M, Tevet Y, Sun J, Stavsky A, Tal S et al. 2019. Synapsins regulate α-synuclein functions. PNAS 116:11116–18
    [Google Scholar]
92. 92. 

    Siksou L, Rostaing P, Lechaire JP, Boudier T, Ohtsuka T et al. 2007. Three-dimensional architecture of presynaptic terminal cytomatrix. J. Neurosci 27:6868–77
    [Google Scholar]
93. 93. 

    Medeiros AT, Soll LG, Tessari I, Bubacco L, Morgan JR. 2017. α-Synuclein dimers impair vesicle fission during clathrin-mediated synaptic vesicle recycling. Front. Cell. Neurosci 11:388
    [Google Scholar]
94. 94. 

    Busch DJ, Oliphint PA, Walsh RB, Banks SM, Woods WS et al. 2014. Acute increase of α-synuclein inhibits synaptic vesicle recycling evoked during intense stimulation. Mol. Biol. Cell 25:3926–41
    [Google Scholar]
95. 95. 

    Eguchi K, Taoufiq Z, Thorn-Seshold O, Trauner D, Hasegawa M, Takahashi T. 2017. Wild-type monomeric α-synuclein can impair vesicle endocytosis and synaptic fidelity via tubulin polymerization at the calyx of Held. J. Neurosci 37:6043–52
    [Google Scholar]
96. 96. 

    Xu J, Wu XS, Sheng J, Zhang Z, Yue HY et al. 2016. α-Synuclein mutation inhibits endocytosis at mammalian central nerve terminals. J. Neurosci 36:4408–14
    [Google Scholar]
97. 97. 

    Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH et al. 2000. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239–52
    [Google Scholar]
98. 98. 

    Garcia-Reitboeck P, Anichtchik O, Dalley JW, Ninkina N, Tofaris GK et al. 2013. Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. Exp. Neurol 248:541–45
    [Google Scholar]
99. 99. 

    Chadchankar H, Yavich L. 2011. Sub-regional differences and mechanisms of the short-term plasticity of dopamine overflow in striatum in mice lacking alpha-synuclein. Brain Res 1423:67–76
    [Google Scholar]
100. 100. 

     Yavich L, Tanila H, Vepsalainen S, Jakala P. 2004. Role of α-synuclein in presynaptic dopamine recruitment. J. Neurosci 24:11165–70
     [Google Scholar]
101. 101. 

     Longhena F, Faustini G, Varanita T, Zaltieri M, Porrini V et al. 2018. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains. Brain Pathol 28:875–88
     [Google Scholar]
102. 102. 

     Kile BM, Guillot TS, Venton BJ, Wetsel WC, Augustine GJ, Wightman RM. 2010. Synapsins differentially control dopamine and serotonin release. J. Neurosci 30:9762–70
     [Google Scholar]
103. 103. 

     Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D et al. 2004. Double-knockout mice for α- and β-synucleins: effect on synaptic functions. PNAS 101:14966–71
     [Google Scholar]
104. 104. 

     Abeliovich A, Gitler AD. 2016. Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature 539:207–16
     [Google Scholar]
105. 105. 

     Senior SL, Ninkina N, Deacon R, Bannerman D, Buchman VL et al. 2008. Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein. Eur. J. Neurosci 27:947–57
     [Google Scholar]
106. 106. 

     Anwar S, Peters O, Millership S, Ninkina N, Doig N et al. 2011. Functional alterations to the nigro-striatal system in mice lacking all three members of the synuclein family. J. Neurosci 31:7264–74
     [Google Scholar]
107. 107. 

     Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. 2010. α-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329:1663–67
     [Google Scholar]
108. 108. 

     Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM et al. 2010. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. PNAS 107:19573–78
     [Google Scholar]
109. 109. 

     Oksman M, Tanila H, Yavich L. 2006. Brain reward in the absence of alpha-synuclein. NeuroReport 17:1191–94
     [Google Scholar]
110. 110. 

     Garcia-Reitböck P, Anichtchik O, Bellucci A, Iovino M, Ballini C et al. 2010. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133:2032–44
     [Google Scholar]
111. 111. 

     Sun J, Wang L, Bao H, Premi S, Das U et al. 2019. Functional cooperation of α-synuclein and VAMP2 in synaptic vesicle recycling. PNAS 116:11113–15
     [Google Scholar]
112. 112. 

     Sousa VL, Bellani S, Giannandrea M, Yousuf M, Valtorta F et al. 2009. α-Synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol. Biol. Cell 20:3725–39
     [Google Scholar]
113. 113. 

     Kamp F, Exner N, Lutz AK, Wender N, Hegermann J et al. 2010. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 29:3571–89
     [Google Scholar]
114. 114. 

     Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM et al. 2011. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein α-synuclein. J. Biol. Chem 286:20710–26
     [Google Scholar]
115. 115. 

     Guardia-Laguarta C, Area-Gomez E, Rüb C, Liu Y, Magrane J et al. 2014. α-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci 34:249–59
     [Google Scholar]
116. 116. 

     Ordonez DG, Lee MK, Feany MB. 2018. α-Synuclein induces mitochondrial dysfunction through spectrin and the actin cytoskeleton. Neuron 97:108–24.e6
     [Google Scholar]
117. 117. 

     Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK et al. 2010. Membrane curvature induction and tubulation are common features of synucleins and apolipoproteins. J. Biol. Chem 285:32486–93
     [Google Scholar]
118. 118. 

     Middleton ER, Rhoades E. 2010. Effects of curvature and composition on α-synuclein binding to lipid vesicles. Biophys. J 99:2279–88
     [Google Scholar]
119. 119. 

     Pranke IM, Morello V, Bigay J, Gibson K, Verbavatz JM et al. 2011. α-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. J. Cell Biol 194:89–103
     [Google Scholar]
120. 120. 

     Westphal CH, Chandra SS. 2013. Monomeric synucleins generate membrane curvature. J. Biol. Chem 288:1829–40
     [Google Scholar]
121. 121. 

     Daumke O, Roux A, Haucke V. 2014. BAR domain scaffolds in dynamin-mediated membrane fission. Cell 156:882–92
     [Google Scholar]
122. 122. 

     Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS. 2014. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci 34:9364–76
     [Google Scholar]
123. 123. 

     Fulop T, Radabaugh S, Smith C. 2005. Activity-dependent differential transmitter release in mouse adrenal chromaffin cells. J. Neurosci 25:7324–32
     [Google Scholar]
124. 124. 

     Aoki R, Kitaguchi T, Oya M, Yanagihara Y, Sato M et al. 2010. Duration of fusion pore opening and the amount of hormone released are regulated by myosin II during kiss-and-run exocytosis. Biochem. J 429:497–504
     [Google Scholar]
125. 125. 

     Logan T, Bendor J, Toupin C, Thorn K, Edwards RH. 2017. α-Synuclein promotes dilation of the exocytotic fusion pore. Nat. Neurosci 20:681–89
     [Google Scholar]
126. 126. 

     Abbineni PS, Bohannon KP, Bittner MA, Axelrod D, Holz RW. 2019. Identification of β-synuclein on secretory granules in chromaffin cells and the effects of α- and β-synuclein on post-fusion BDNF discharge and fusion pore expansion. Neurosci. Lett 699:134–39
     [Google Scholar]
127. 127. 

     Miesenböck G, De Angelis DA, Rothman JE 1998. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature 394:192–95
     [Google Scholar]
128. 128. 

     Alabi AA, Tsien RW. 2013. Perspectives on kiss-and-run: role in exocytosis, endocytosis, and neurotransmission. Annu. Rev. Physiol 75:393–422
     [Google Scholar]
129. 129. 

     Watanabe S, Lehmann M, Hujber E, Fetter RD, Richards J et al. 2014. Nanometer-resolution fluorescence electron microscopy (nano-EM) in cultured cells. Methods Mol. Biol. 1117:503–26
     [Google Scholar]
130. 130. 

     Staal RG, Mosharov EV, Sulzer D. 2004. Dopamine neurons release transmitter via a flickering fusion pore. Nat. Neurosci 7:341–46
     [Google Scholar]
131. 131. 

     Silm K, Yang J, Marcott PF, Asensio CS, Eriksen J et al. 2019. Synaptic vesicle recycling pathway determines neurotransmitter content and release properties. Neuron 102:786–800.e5
     [Google Scholar]
132. 132. 

     Berberian K, Torres AJ, Fang Q, Kisler K, Lindau M. 2009. F-actin and myosin II accelerate catecholamine release from chromaffin granules. J. Neurosci 29:863–70
     [Google Scholar]
133. 133. 

     Nightingale TD, White IJ, Doyle EL, Turmaine M, Harrison-Lavoie KJ et al. 2011. Actomyosin II contractility expels von Willebrand factor from Weibel-Palade bodies during exocytosis. J. Cell Biol 194:613–29
     [Google Scholar]
134. 134. 

     Wen PJ, Grenklo S, Arpino G, Tan X, Liao HS et al. 2016. Actin dynamics provides membrane tension to merge fusing vesicles into the plasma membrane. Nat. Commun 7:12604
     [Google Scholar]
135. 135. 

     Anantharam A, Bittner MA, Aikman RL, Stuenkel EL, Schmid SL et al. 2011. A new role for the dynamin GTPase in the regulation of fusion pore expansion. Mol. Biol. Cell 22:1907–18
     [Google Scholar]
136. 136. 

     Zhao WD, Hamid E, Shin W, Wen PJ, Krystofiak ES et al. 2016. Hemi-fused structure mediates and controls fusion and fission in live cells. Nature 534:548–52
     [Google Scholar]
137. 137. 

     Eliezer D, Kutluay E, Bussell R Jr., Browne G. 2001. Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol 307:1061–73
     [Google Scholar]
138. 138. 

     Chandra S, Chen X, Rizo J, Jahn R, Sudhof TC. 2003. A broken α-helix in folded α-Synuclein. J. Biol. Chem 278:15313–18
     [Google Scholar]
139. 139. 

     Georgieva ER, Ramlall TF, Borbat PP, Freed JH, Eliezer D. 2008. Membrane-bound α-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J. Am. Chem. Soc 130:12856–57
     [Google Scholar]
140. 140. 

     Jao CC, Hegde BG, Chen J, Haworth IS, Langen R 2008. Structure of membrane-bound α-synuclein from site-directed spin labeling and computational refinement. PNAS 105:19666–71
     [Google Scholar]
141. 141. 

     Ferreon AC, Gambin Y, Lemke EA, Deniz AA 2009. Interplay of α-synuclein binding and conformational switching probed by single-molecule fluorescence. PNAS 106:5645–50
     [Google Scholar]
142. 142. 

     Mizuno N, Varkey J, Kegulian NC, Hegde BG, Cheng N et al. 2012. Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. J. Biol. Chem 287:29301–11
     [Google Scholar]
143. 143. 

     Kobbersmed JR, Grasskamp AT, Jusyte M, Böhme MA, Ditlevsen S et al. 2020. Rapid regulation of vesicle priming explains synaptic facilitation despite heterogeneous vesicle:Ca²⁺ channel distances. eLife 9:e51032
     [Google Scholar]
144. 144. 

     Lesage S, Anheim M, Letournel F, Bousset L, Honore A et al. 2013. G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann. Neurol 23:459–71
     [Google Scholar]
145. 145. 

     Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM et al. 2013. A novel α-synuclein missense mutation in Parkinson disease. Neurology 80:1062–64
     [Google Scholar]
146. 146. 

     Lazaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T et al. 2014. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLOS Genet 10:e1004741
     [Google Scholar]
147. 147. 

     Newberry RW, Leong JT, Chow ED, Kampmann M, DeGrado WF. 2020. Deep mutational scanning reveals the structural basis for α-synuclein activity. Nat. Chem. Biol 16:653–59
     [Google Scholar]
148. 148. 

     Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. 2004. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science 305:1292–95
     [Google Scholar]
149. 149. 

     Golovko MY, Rosenberger TA, Faergeman NJ, Feddersen S, Cole NB et al. 2006. Acyl-CoA synthetase activity links wild-type but not mutant α-synuclein to brain arachidonate metabolism. Biochemistry 45:6956–66
     [Google Scholar]
150. 150. 

     Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. 2005. α-Synuclein cooperates with CSPα in preventing neurodegeneration. Cell 123:383–96
     [Google Scholar]
151. 151. 

     Cadieux-Dion M, Andermann E, Lachance-Touchette P, Ansorge O, Meloche C et al. 2013. Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease. Clin. Genet 83:571–75
     [Google Scholar]
152. 152. 

     Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G et al. 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New Engl. J. Med. 361:1651–61
     [Google Scholar]
153. 153. 

     Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ et al. 2011. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37–52
     [Google Scholar]
154. 154. 

     Mazzulli JR, Zunke F, Tsunemi T, Toker NJ, Jeon S et al. 2016. Activation of β-glucocerebrosidase reduces pathological α-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons. J. Neurosci 36:7693–706
     [Google Scholar]
155. 155. 

     Henderson MX, Sedor S, McGeary I, Cornblath EJ, Peng C et al. 2020. Glucocerebrosidase activity modulates neuronal susceptibility to pathological α-synuclein insult. Neuron 105:822–36.e7
     [Google Scholar]
156. 156. 

     Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC et al. 2017. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. Science 357:1255–61
     [Google Scholar]
157. 157. 

     Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M 1998. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. PNAS 95:6469–73
     [Google Scholar]
158. 158. 

     Galvin JE, Uryu K, Lee VM, Trojanowski JQ 1999. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein. PNAS 96:13450–55
     [Google Scholar]
159. 159. 

     Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE et al. 2019. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22:1099–109
     [Google Scholar]